Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesMammalian target of rapamycin: A new target in prostate cancer
Urologic Oncology: Seminars and Original Investigations, 07/27/09
Rai JS et al. – Molecular targets in prostate cancer are continually being explored, especially in the poor–prognosis androgen–independent phase of the disease, for which there are currently few therapeutic options. One such target is the mammalian target of rapamycin (mTOR) protein. In this review, the authors consider the rationale for pursuing mTOR as a therapeutic target in prostate cancer and summarize preclinical and clinical studies of mTOR inhibition in prostate cancer.
Related Articles
Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients
Journal of Dermatological Science, 10/06/09
Relevance Score: 91%
Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs
Nephrology Dialysis Transplantation, 11/17/09
Relevance Score: 89%
Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis
International Journal of Cancer, 11/10/09
Relevance Score: 88%
MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through Eukaryotic Initiation Factor 4E–Binding Protein 1–Mediated Inhibition of Autophagy
Cancer Research, 10/06/09
Relevance Score: 87%
Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML
European Journal of Internal Medicine, 11/06/09
Relevance Score: 85%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial
Journal of Clinical Oncology, 12/10/09
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer
Journal of the National Cancer Institute, 12/10/09
Botulinum neurotoxin A for benign prostatic hyperplasia
Current Opinion in Urology, 12/10/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence
Cancer, 12/11/09
[F18]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study
European Journal of Cancer, 12/11/09
HNF1B and JAZF1 genes, diabetes, and prostate cancer risk
The Prostate, 12/11/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
The current status of robot-assisted laparoscopic prostatectomy
Current Opinion in Urology, 12/11/09
Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence
Cancer, 12/11/09
Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia
Current Opinion in Urology, 12/11/09
Article Search
Sponsor